Patients with programmed death-ligand 1 positive (PD-L1+), locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) have a poor prognosis and treatment options are limited. Sitravatinib, selective tyrosine kinase inhibitor, reduces the number of myeloid-derived suppressor cells regulatory T cells, promotes expansion migration antitumor cytotoxic increases ratio M1/M2-pola...

Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies. Although preclinical studies suggest that inhibiting programmed cell death-ligand 1/programmed cell death-1 interactions might also be highly effective in hematological malignancies, remarkably few clinical trials have ...